The use of ITGA2 blocking antibodies inhibits migration and induces apoptosis of gastric cancer cells [23,25], while overexpression of ITGA2 stimulates PD-L1 expression by activating the STAT3 signaling cascade, leading to the more aggressive behavior of malignant pancreatic cells [24]. Here, ITGA2 is linked to gastric cancer.